Facing erosion of its mighty Eylea (aflibercept) franchise and near-term loss of exclusivity with Dupixent (dupilumab), Regeneron Pharmaceuticals Inc. took a blow as one of two phase III trials with ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs; The agreement includes pr ...

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

If you or someone you know has chronic asthma do read this article to know how biologics can potentially help in treating the condition ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

The poster presentations will be available on Connect’s website under the Presentations and Publications section.

In a clinical report published online May 19 in Pediatrics, the American Academy of Pediatrics presents updated guidance for ...

Real-world data from Australian patients show that upadacitinib demonstrates strong efficacy in treating atopic dermatitis, ...